Enasidenib enters domestic medical insurance

Enasidenib (Enasidenib) is an oral medicine used to treat adult patients with acute myeloid leukemia (AML), a cancer of the blood and bone marrow. This approach can be used if a patient's cancer has a mutation in a specific gene calledIDH2 (isocitrate dehydrogenase-2). Ensidipine is used in patients with acute myeloid leukemia who have relapsed after initial treatment or who have not responded to treatment (refractory). It is not known whether ensidipine is safe or effective in children.

Ensidipine is approved for real-timeIDH2 testing, a diagnostic method that detects specific mutations in the IDH2 gene in patients with acute myeloid leukemia. Mutations in the IDH2 gene may cause immature blood cells to become cancerous and divide uncontrollably, leading to acute myeloid leukemia. If the patient can be treated with this drug, he should take ensidipine strictly according to the doctor's instructions. The recommended dose is 100 mg orally once a day. Take this medicine at about the same time each day without splitting or crushing the tablets.

Ensiidi plain investigational medicine is not yet on the market in China, nor has it entered the scope of national medical insurance through relevant policies. The price of ensidipine plain medicine when it is launched overseas is very high, and the price of each box may be around 30,000 yuan (the price may fluctuate due to the exchange rate). Currently, there are cheaper generic encidipine drugs produced by other pharmaceutical companies overseas. For example, the price of Specification50mg*60 tablets produced by a Bangladesh pharmaceutical factory may be around 4,000 yuan per box (the price may fluctuate due to exchange rates). Its drug ingredients are basically the same as those of the original encidipine generic drug.